AUSTIN, Nov. 19, 2020 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics
company developing simple, easy to use, cost effective blood tests
to help diagnose a range of cancers and other diseases, has
announced that Dr. Mark Eccleston, a
founding scientist and Business Development Director at Volition,
will today present preliminary results from its proof of concept
clinical studies focused on monitoring disease progression of
COVID-19 as part of the "Innovative COVID-19 Diagnostics"
session at the virtual MEDICA LABMED FORUM.
Volition's initial studies demonstrated that symptomatic
COVID-19 patients have elevated circulating nucleosomes and, as a
result, Volition has filed a novel patent for monitoring disease
progression of COVID-19 and other NETosis associated infections.
Preliminary results from ongoing longitudinal COVID-19 studies are
expected to be released before the end of 2020. The Company plans
to utilise the results of these current trials and other ongoing
studies to further its aim of developing a clinically useful
product to help in the COVID-19 pandemic, and potentially in other
infections with dangerous complications caused by NETosis including
influenza and sepsis.
The presentation, "Circulating nucleosomes as potential
prognostic markers for COVID-19 disease severity" will outline the
data compiled so far to support the Company's use of its Nu.Q™
Nucleosomics™ technology to identify cell free circulating
nucleosomes associated with elevated NETosis - the body's immune
response to an infection - in "at risk" individuals with
COVID-19.
Data from two independent cohorts of COVID-19 positive patients
with quantitative nucleosome immunoassays showed that nucleosomes
were highly elevated in the plasma of patients with severe
COVID-19, relative to healthy control subjects. The data showed
that the levels of both histone 3.1 variant and citrullinated
nucleosomes increased with disease severity.
The highest levels of nucleosomes were found in patients
requiring artificial ventilation or extracorporeal oxygenation.
Volition believes that it is possible, therefore, that nucleosomes
could be used to monitor disease progression in COVID-19 positive
patients and potentially other diseases such as influenza and
sepsis.
Nu.Q H3.1 increased
with disease severity.
Early identification and triaging of at-risk COVID-19 patients
to determine those most likely to deteriorate and require critical
care would enable both improved outcomes for patients and a more
efficient use of critical care resources for healthcare
providers.
Dr. Eccleston said: "We are very pleased to be invited to
present data at the MEDICA LABMED FORUM on the work we are doing to
use circulating nucleosomes to monitor COVID-19. As we see the
number of cases rise again worldwide, we believe more than ever
that the ability to understand disease progression and to manage
resources accordingly is an important and still unmet need. We look
forward to announcing further data soon."
You can view the presentation here:
https://volition.com/resources/downloads/Volition-Medica-COVID-presentation.pdf
About Volition
Volition is a multi-national epigenetics company developing
simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. The tests are based on the science
of NucleosomicsTM, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid
- an indication that disease is present. Volition is primarily
focused on human diagnostics but also has a subsidiary focused on
animal diagnostics.
Volition's research and development activities are centered in
Belgium, with a small laboratory
in California and additional
offices in Texas, London and Singapore, as the company focuses on bringing
its diagnostic products to market.
For more information about Volition, visit Volition's website
volition.com or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volition.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Jen Lewis,
Pegasus
jen.lewis@thisispegasus.co.uk
+44 (0)7809
867943
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the timing, completion and delivery of data from clinical
studies, the effectiveness of Volition's blood-based diagnostic and
prognostic tests, and Volition's ability to develop and
successfully commercialize such test platforms for early detection
of cancer and other diseases as well as serving as a diagnostic or
prognostic tool for COVID-19. Volition's actual results may differ
materially from those indicated in these forward-looking statements
due to numerous risks and uncertainties, including, without
limitation, results of studies testing the efficacy of its tests.
For instance, if Volition fails to develop and commercialize
diagnostic or prognostic products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic or prognostic products Volition
might develop; Volition's failure to secure adequate intellectual
property protection; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics market and its rapid
technological change; downturns in domestic and foreign economies;
and other risks identified in Volition's most recent Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, as well as other
documents that Volition files with the Securities and Exchange
Commission. These statements are based on current expectations,
estimates and projections about Volition's business based, in part,
on assumptions made by management. These statements are not
guarantees of future performance and involve risks, uncertainties
and assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q™ and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-covid-19-data-at-medica-2020-301177004.html
SOURCE VolitionRx Ltd